LifeMD (LFMD) Stock Price, News & Analysis

Company Overview

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care. Patients access virtual consultations, follow-up visits and medication management through a flat-fee membership model. Specialized programs address conditions such as erectile dysfunction, hair loss, thyroid disorders and metabolic health, while integrated pharmacy partnerships allow users to receive prescribed treatments directly at home.

Since its founding, LifeMD has expanded through strategic acquisitions of complementary telehealth businesses to broaden its clinical capabilities and patient reach. The company’s brands now encompass platforms focused on preventive care, chronic disease management and women’s health, creating a multi-specialty virtual care network. LifeMD serves patients across the United States and continually invests in digital technology to improve care coordination and patient engagement.

Headquartered in Florida, LifeMD went public in early 2021 and trades on the Nasdaq under the ticker LFMD. The company is led by a management team with deep experience in healthcare delivery, digital innovation and telemedicine. LifeMD continues to leverage its unified platform to address evolving consumer preferences for accessible, cost-effective virtual care.

Key Stats

• Today's Range: $3.05 to $3.23
• 50-Day Range: $3.09 to $4.91
• 52-Week Range: $2.56 to $7.32
• Volume: 405,464 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $153.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.57
• Consensus Rating: Moderate Buy

LifeMD Stock Analysis - MarketRank™

LifeMD scored higher than 76% of companies evaluated by MarketBeat, and ranked 163rd out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LifeMD has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

LifeMD has a consensus price target of $7.57, representing about 139.2% upside from its current price of $3.17.

Amount of Analyst Coverage

LifeMD has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LifeMD are expected to grow in the coming year, from ($0.48) to $0.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LifeMD is -63.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LifeMD is -63.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LifeMD has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.41% of the float of LifeMD has been sold short.

Short Interest Ratio / Days to Cover

LifeMD has a short interest ratio ("days to cover") of 4.74.

Change versus previous month

Short interest in LifeMD has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LifeMD does not currently pay a dividend.

Dividend Growth

LifeMD does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

LifeMD has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for LifeMD this week, compared to 7 articles on an average week.

Search Interest

8 people have searched for LFMD on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

3 people have added LifeMD to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LifeMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.22% of the stock of LifeMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.52% of the stock of LifeMD is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/01/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:LFMD
• CIK: 948320
• Web: www.lifemd.com
• Phone: (866) 351-5907
• Fax: N/A
• Employees: 230
• Year Founded: 2016

Price Target and Rating

• Average Price Target for LifeMD: $7.57
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +138.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $14.35 million
• Net Margins: 0.10%
• Pretax Margin: -10.51%
• Return on Equity: -168.23%
• Return on Assets: -31.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.90
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $194.05 million
• Price / Sales: 0.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 6.61

Miscellaneous

• Outstanding Shares: 48,200,000
• Free Float: 39,901,000
• Market Cap: $153.04 million
• Optionable: Optionable
• Beta: 2.02